Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Moderate Buy” by Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $106.25.

PCVX has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Vaxcyte in a research note on Saturday, September 27th. Finally, Cowen reissued a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PCVX. AlphaQuest LLC bought a new position in Vaxcyte during the first quarter valued at about $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Vaxcyte during the first quarter valued at about $35,000. CWM LLC boosted its stake in Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after buying an additional 1,115 shares in the last quarter. IFP Advisors Inc boosted its stake in Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after buying an additional 1,306 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Vaxcyte by 176.7% during the second quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock valued at $70,000 after buying an additional 1,380 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $41.87 on Wednesday. Vaxcyte has a 1 year low of $27.66 and a 1 year high of $118.62. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of -10.19 and a beta of 1.12. The business has a fifty day moving average of $32.98 and a 200-day moving average of $34.52.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the prior year, the company earned ($1.10) earnings per share. On average, equities research analysts predict that Vaxcyte will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.